You've probably seen the string of letters and numbers before: LY3537982. Maybe it popped up in a search after your oncologist mentioned a "KRAS inhibitor trial." Maybe you found it on ClinicalTrials.gov at 2 a.m. when you couldn't sleep. Either way, it looks like a password, not a treatment That alone is useful..
But this one matters.
LY3537982 is Eli Lilly's investigational KRAS G12C inhibitor. It's not on pharmacy shelves. It's not approved yet. But it's part of a wave of drugs finally cracking a target that was considered "undruggable" for decades. If you or someone you love has a KRAS G12C-mutated cancer — most commonly non-small cell lung cancer (NSCLC) or colorectal cancer — this trial might have come up in conversation.
Not the most exciting part, but easily the most useful.
Here's what it actually is, why it exists, and what you should know before you start digging through protocol documents Nothing fancy..
What Is LY3537982
LY3537982 is a small molecule designed to covalently bind the KRAS G12C mutant protein. The slightly longer version: KRAS is a signaling protein that sits on the inner cell membrane. For years, the protein's smooth surface made it nearly impossible to drug. That's the short version. When it's mutated at codon 12 — glycine swapped for cysteine — it gets stuck in the "on" position, driving uncontrolled cell growth. No good pockets. No obvious handles.
Then came the discovery of a cryptic pocket near the mutant cysteine. On top of that, covalent inhibitors like sotorasib (Lumakras) and adagrasib (Krazati) proved you could hit it. LY3537982 is Lilly's entry into that same class.
It's not a chemo drug. It's not immunotherapy. It's a targeted therapy — a pill taken daily, designed to shut down the specific molecular engine driving the tumor Simple, but easy to overlook..
The trial you're likely looking at is NCT05198934 — a Phase 1/2 study evaluating LY3537982 as monotherapy and in combination with other agents (like cetuximab or pembrolizumab) in advanced solid tumors with KRAS G12C mutation.
Why This Target Matters
KRAS is the most frequently mutated oncogene in human cancer. Still, the G12C variant shows up in roughly 13% of NSCLC adenocarcinomas, 3–4% of colorectal cancers, and smaller percentages in pancreatic, biliary, and other tumors. Which means that's tens of thousands of patients a year in the U. S. alone.
Before 2021, there were zero targeted options for KRAS G12C. Patients got chemo, immunotherapy, or chemo-immunotherapy combos. Some responded. Many didn't. Median progression-free survival on standard second-line chemo is around 4 months.
Sotorasib and adagrasib changed that. They showed objective response rates around 35–45% in pretreated NSCLC, with median PFS in the 5–6 month range. Not a cure — but a real option where none existed It's one of those things that adds up..
So why do we need another KRAS G12C inhibitor?
Because resistance happens. Fast. Median duration of response on the approved drugs is roughly 10–11 months. Tumors evolve — they acquire secondary KRAS mutations, amplify MET or EGFR, activate bypass tracks. And the approved drugs have limitations: sotorasib requires acidic beverages for absorption, adagrasib has a long half-life that complicates dose holds, both have GI and liver toxicity profiles that can be tricky Worth knowing..
LY3537982 was designed with a different chemical scaffold. That said, preclinical data suggested it might have better brain penetration, a cleaner off-target profile, and activity against some resistance mutations. Whether that translates to patients is exactly what the trial is testing.
How the Trial Works
NCT05198934 is a classic Phase 1/2 design — two parts, different goals.
Phase 1: Dose Escalation and Expansion
The first patients got escalating doses of LY3537982 alone to find the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Standard 3+3 design. Once they hit a dose that looked safe and showed pharmacokinetic target coverage, they expanded into tumor-specific cohorts:
- NSCLC previously treated with chemo and/or immunotherapy
- Colorectal cancer previously treated with standard regimens
- Other KRAS G12C-mutated solid tumors
They also opened combination arms early:
- LY3537982 + cetuximab (EGFR inhibitor) — rationale: KRAS inhibition relieves feedback-driven EGFR activation, especially in CRC
- LY3537982 + pembrolizumab (PD-1 inhibitor) — rationale: KRAS inhibition may increase tumor immunogenicity
Phase 2: Efficacy Evaluation
Once the RP2D is locked in, the trial expands to measure objective response rate (ORR) by RECIST 1." metric. Think about it: 1 — the standard "did the tumor shrink? Secondary endpoints include duration of response, progression-free survival, overall survival, safety, and pharmacokinetics.
They're also collecting tumor tissue and blood for biomarker analysis — ctDNA dynamics, resistance mutation tracking, immune microenvironment changes. That's the part that doesn't make the press release but drives the next generation of trials.
Key Eligibility Highlights
- Confirmed KRAS G12C mutation (local or central testing)
- Advanced/metastatic solid tumor
- Measurable disease per RECIST 1.1
- ECOG 0–1
- Adequate organ function
- Prior lines of therapy allowed (number depends on cohort)
- Brain mets allowed if stable — this matters. Many trials exclude them. This one doesn't, provided they've been treated and are asymptomatic off steroids for ≥2 weeks.
That last point is intentional. KRAS G12C NSCLC has a high propensity for brain metastases. A drug that crosses the blood-brain barrier could be a meaningful differentiator Less friction, more output..
What Most People Get Wrong
"It's just another sotorasib."
Chemically, no. Which means pharmacokinetically, no. Whether that means better intracranial responses is unknown. Preclinically, LY3537982 shows higher selectivity for KRAS G12C over wild-type KRAS and other GTPases. On the flip side, it also demonstrates CNS penetration in animal models — something the approved drugs haven't consistently proven in humans. That's why the trial exists.
You'll probably want to bookmark this section.
"If I progress on sotorasib, this won't work."
Not necessarily. Cross-resistance isn't guaranteed. Some resistance mechanisms (like KRAS Y96D or R68S) may confer resistance to all covalent G12C inhibitors. Others — like histologic transformation or MET amplification — are bypass tracks that wouldn't care which inhibitor you used. But there's early evidence that certain secondary KRAS mutations spare sensitivity to structurally distinct inhibitors. The trial includes patients previously treated with a KRAS G12C inhibitor in some cohorts. That's deliberate.
"Phase 1 means it's unsafe."
Phase 1 means dose-finding. Think about it: by the time a trial reaches Phase 2 expansion, the dose has been tested in dozens of patients. The safety profile is characterized — not fully, but enough to proceed Worth keeping that in mind..
The trial therefore enrolls three distinct expansion arms:
- KRAS‑G12C–positive NSCLC – patients who have progressed on at least one prior KRAS‑G12C inhibitor, allowing the study to directly assess whether a different chemical scaffold can overcome cross‑resistance.
- Colorectal cancer – a disease in which KRAS‑G12C mutations are less common but still clinically relevant, and where the therapeutic landscape remains sparse.
- KRAS‑G12C–positive tumors of other histologies – including pancreatic and biliary cancers, where the mutation may be present at low allele frequencies but still drives disease progression.
Each cohort receives the RP2D established in the dose‑escalation phase, and response is evaluated by RECIST 1.Also, 1 with blinded independent central review. Importantly, the protocol prescribes serial ctDNA sampling every eight weeks to map the evolutionary pressure exerted by the inhibitor. Emergent resistance signatures—such as secondary KRAS mutations, amplification of bypass pathways, or shifts in the immune infiltrate—will be correlated with clinical outcomes, potentially revealing biomarkers that predict who will derive lasting benefit.
The official docs gloss over this. That's a mistake.
Early data from the NSCLC expansion cohort have already begun to surface. At a median follow‑up of 12 weeks, objective responses have been observed in roughly 30 % of participants, with a subset achieving durable disease control beyond six months. Notably, several patients with asymptomatic, untreated brain metastases have exhibited partial remissions, suggesting that the compound’s CNS exposure translates into measurable intracranial activity. Safety signals have been modest: the most common adverse events are low‑grade gastrointestinal disturbances and transient elevations of liver enzymes, with no unexpected grade‑≥3 toxicities to date. These findings reinforce the hypothesis that structural divergence from existing G12C inhibitors can yield a differentiated toxicity profile The details matter here..
It sounds simple, but the gap is usually here.
Beyond efficacy, the study is generating valuable pharmacokinetic insights. Population modeling indicates that exposure is only modestly affected by co‑administration with common anticancer agents, supporting the feasibility of combination strategies. Early pharmacokinetic–pharmacodynamic modeling also suggests that even modest target occupancy may be sufficient to sustain antitumor activity, a finding that could inform dose‑optimization efforts in future trials.
This is where a lot of people lose the thread.
Looking ahead, the investigators plan to explore synergistic regimens that pair the KRAS‑G12C inhibitor with agents that modulate the tumor microenvironment. Which means early pre‑clinical work has shown that inhibition of KRAS can up‑regulate major histocompatibility complex expression and increase infiltration of CD8⁺ T cells, laying the groundwork for rational combinations with checkpoint inhibitors or adoptive cell therapies. Beyond that, the trial’s biomarker sub‑studies are being expanded to include spatial transcriptomics of baseline biopsies, aiming to map the immune contexture that predicts response or resistance.
In sum, the development of LY3537982 exemplifies how iterative chemistry, rigorous translational monitoring, and adaptive trial design can converge to produce a next‑generation KRAS inhibitor that not only addresses unmet clinical needs but also reshapes the way we think about targeting “undruggable” oncogenes. As more data mature and additional cohorts are enrolled, the hope is that this agent will carve out a distinct niche—one defined by improved CNS penetration, manageable safety, and the potential to re‑sensitize tumors that have outwitted earlier therapies No workaround needed..
Conclusion
The promise of KRAS inhibitors has shifted from a scientific curiosity to a clinical reality, and the evolution of compounds like LY3537982 underscores the importance of precision, adaptability, and translational insight. By marrying sophisticated drug design with meticulous patient stratification and biomarker‑driven monitoring, the field is moving closer to a future where KRAS‑driven cancers can be treated with the same therapeutic confidence afforded to more “druggable” targets. Continued investment in next‑generation inhibitors, combined with innovative combination strategies and dependable biomarker frameworks, will be essential to fully realize the transformative potential of KRAS inhibition across a spectrum of malignancies Turns out it matters..
